French R&D Collaboration in Stem Cell Engineering
November 3, 2009 – 10:06 am
By developing the technology to create custom induced pluripotent stem cells (iPSCs), that is, adult cells reprogrammed to a stem cell-like state, three French biotech clusters will be able to provide an unlimited, noncontroversial, supply of human cells. These cells will meet an unmatched standard of quality and ultimately speed up the process of therapeutic innovation, says an announcement from the Invest in France Agency. It goes on to comment that the number of organisations coming together in this collaboration between companies and research institutes is unprecedented.
Co-sponsored by the major French clusters: Alsace BioValley (Strasbourg), Cancer Bio Santé (Toulouse) and Medicen (Paris), the project, named SHIP-In, has a total budget of $6.5 million, and has secured financial support from the French government totalling $3.1 million.
France’s commitment to advancing the healthcare industry, from regenerative medicine and neurodegenerative diseases to vaccines and vaccinotherapy, goes beyond project-specific funding. Since 2005, France has established eight official innovation clusters that focus solely on biotechnology and healthcare. Projects within these clusters are selected for funding by the French government following a bi-annual request for project proposals.
Fabrice Etienvre, CEO of Invest in France UK and Ireland, said, “France’s commitment to innovation, coupled with the best R&D tax incentives in Europe, mean companies choosing to come to France and to the innovative clusters find themselves in a highly supportive environment. SHIP-In is an excellent example of the various resources, expertise and collaborative opportunities that are available in France.”
Annie EllertonTags: Invest in France, Stem cell research
3 Responses to “French R&D Collaboration in Stem Cell Engineering”
For autologous partial cell rejuvenation the
PiPS stemm cell method is not the only one. There may be an other epigenetic method called “Partial Cloning”(PCL) which is faster and does not need any pluripotent return to embryonic like cells. PCL can allows to permanently keep the differentiated cell status during its monopotent partial biological age reprogramming.
By Fred Zacouto, M.D., Ph.D. on Nov 6, 2009
Two-photon-polymerisation (2pp), allowing to generate true three-dimensional nanostructures has graet potential.
We have deep knowledge about lasers, polymers and biomaterials. Materials used and end product applications are a key-factor when choosing the laser applicable for the process.
In order to develop the process even further, and for various applications we are looking for cooperation partners in various industries.
Olli Saarniaho
CEO
By Olli Saarniaho on Nov 11, 2009